[Federal Register Volume 72, Number 195 (Wednesday, October 10, 2007)]
[Notices]
[Pages 57595-57596]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E7-19941]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Devices for 
Countercurrent Chromatography

AGENCY: National Institutes of Health, Public Health Service, HHS.

[[Page 57596]]


ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
an exclusive worldwide license to practice the invention embodied in: 
HHS Ref. No. E-321-2007 ``Second Generation Improved Spiral Tube 
Support for Countercurrent Chromatography'' to CC Biotech LLC, a 
company incorporated under the laws of the State of Maryland having its 
headquarters in Rockville, Maryland. The United States of America is 
the assignee of the rights of the above inventions. The contemplated 
exclusive license may be granted in a field of use limited to devices 
and components for centrifugal or countercurrent chromatographic 
purification, isolation, or preparation of biomolecules and 
macromolecules.

DATES: Only written comments and/or applications for a license received 
by the NIH Office of Technology Transfer on or before December 10, 2007 
will be considered.

ADDRESSES: Requests for a copy of the patent application, inquiries, 
comments and other materials relating to the contemplated license 
should be directed to: Michael A. Shmilovich, Esq., Office of 
Technology Transfer, National Institutes of Health, 6011 Executive 
Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 435-
5019; Facsimile: (301) 402-0220; E-mail: [email protected]. A 
signed confidentiality nondisclosure agreement will be required to 
receive copies of any patent applications that have not been published 
by the United States Patent and Trademark Office or the World 
Intellectual Property Organization.

SUPPLEMENTARY INFORMATION: The patents and patent applications intended 
for licensure disclose or cover the following:
[GRAPHIC] [TIFF OMITTED] TN10OC07.006

    The support compactly holds spirally wound plastic tubing at a 
desired spiral pitch without connection. When mounted on the existing 
high-speed countercurrent chromatographic centrifuge, it will produce 
separation of bioactive compounds including proteins, nucleic acids, 
polysaccharides, and small molecular weight compounds from natural 
products without loss of samples in the separation column.
    The present invention is an improvement on a spiral disc previously 
reported under E-014-2003 (now abandoned) which was published as WO 
2004/085020. That disc differed in that the prior version the radial 
channels represented in the figure on the right (e.g., I1-
O4; I4-O3, etc.) went all the way 
through the disc and ended at the outer wall and the center, thereby 
creating a channel that forced tubing to wrap around the device to re-
enter the spiral grooves. Here, the direction of the tubing through the 
interleaved spiral grooves is continuous and the transition points 
between grooves are smoother. The design effectively eliminates about 5 
cm of ``dead-space,'' and allows for the plates to be stackable; which 
was impossible with the previous design.
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless, within sixty 
(60) days from the date of this published notice, NIH receives written 
evidence and argument that establishes that the grant of the license 
would not be consistent with the requirements of 35 U.S.C. 209 and 37 
CFR 404.7.
    Properly filed competing applications for a license filed in 
response to this notice will be treated as objections to the 
contemplated license. Comments and objections submitted in response to 
this notice will not be made available for public inspection, and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: October 1, 2007.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. E7-19941 Filed 10-9-07; 8:45 am]
BILLING CODE 4140-01-P